SAN FRANCISCO, CA, July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma, Inc. (OTCPK: ONPH) is pleased and honored to announce the appointment of Stefan Gruenwald (MD. Ph.D) to its Advisory Board. Dr. S. Gruenwald brings more than 30 years of experience and vast knowledge in both the clinical, scientific and business fields to the company. His contribution to meeting the vision, mission and goals are a great asset to the company. Dr. Gruenwald has had an impressive career as the former VP of R&D at Becton Dickenson, the former CSO at Pharmingen and the former President at Orbigen. He is currently a co founder and president of Diagnomics.
"I am delighted to join a young and dynamic company like Oncology Pharma and I hope to be able to make significant contributions to its profitable growth," said Dr. Gruenwald. "I am honored to be part of an exciting management team and I believe that this company has a bright future."
In addition, Oncology Pharma is pleased to announce its new website: www.oncology-pharma.com.
About Oncology Pharma, Inc.
ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”) is a pioneering oncology company dedicated to developing, manufacturing, and commercializing therapeutics. The Company has licensed Tulynode's patent pending Autologous Immuno-therapy for durable therapy response using an extracorporeal device. The Company is currently engaging in research and development of therapeutics for oncology, and prides itself for having a world-class Advisory Board that keeps the Company in the forefront of developing technologies in cancer research, biotechnology, and healthcare.
Forward-looking Statements
Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the Company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include risks related to licensing arrangements and joint ventures, including the need to negotiate the definitive agreements for the relationships; possible failure to realize anticipated benefits of business relationships; and, costs of providing funding to these business relationships. Other risks and uncertainties relating to the Company include, among other things, current negative operating cash flows and a need for additional funding to finance our operating plan; the terms of any further financing, which may be highly dilutive and may include onerous terms; unexpected costs and operating deficits, and lower than expected sales and revenues; uncertain willingness and ability of customers to adopt new technologies and other factors that may affect further market acceptance; adverse economic conditions; adverse results of any legal proceedings; the volatility of our operating results and financial condition; inability to attract or retain qualified senior management personnel, including sales and marketing personnel; our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners and with any strategic or joint venture partners; the impact of competition; the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; management of growth; and, other risks and uncertainties. This is not a solicitation to buy or sell securities and does not purport to be an analysis of the Company's financial position.